6 completed, 4 recruiting, 1 active not recruiting, 1 unknown. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Recruiting 4, Active not recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Cutaneous T Cell Lymphoma: new trials by email Literature Review of Cutaneous T Cell Lymphoma trials Research Report on Cutaneous T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas Pembrolizumab, Mogamulizumab - Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 23 | 2023-12-06 | 2026-05-05 |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Completed | Ellen Kim, MD | 10 | 2023-08-21 | 2026-02-09 |
| Photopheresis in Early-stage Mycosis Fungoides UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Recruiting | Columbia University | 74 | 2021-05-08 | 2026-04-27 |
| A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) Pembrolizumab, Radiotherapy - Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Active not recruiting | University College, London | 46 | 2019-01-15 | 2024-12-09 |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Placebo, CD11301 0.03%, CD11301 0.06% - Cutaneous T Cell Lymphoma | Phase 2 | Completed | Galderma R&D | 86 | 2017-12-19 | 2021-04-08 |
| Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Dimethyl fumarate - Cutaneous T Cell Lymphoma | Phase 2 | Completed | Universitätsmedizin Mannheim | 25 | 2015-09-01 | 2023-03-31 |
| Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Topical resiquimod 0.06%, topical resiquimod 0.03% - Cutaneous T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 13 | 2012-02-01 | 2019-08-13 |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 46 | 2010-07-01 | 2015-03-03 |
| Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Lenalidomide - Cutaneous T Cell Lymphoma | Phase 2 | Unknown | Florida Academic Dermatology Centers | 10 | 2010-05-01 | 2010-05-28 |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Romidepsin - Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 131 | 2001-03-08 | 2017-05-16 |
Lymphoma, T-Cell, Cutaneous (12) · Mycosis Fungoides (5) · Lymphoma, T-Cell (3) · Lymphoma (2) · Lymphoma, T-Cell, Peripheral (2) · Sezary Syndrome (2) · Graft vs Host Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoma, Non-Hodgkin (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (10) · Lymphoma, T-Cell (9) · Hematologic Diseases (2) · Leukemia, Lymphoid (2) · Leukemia, T-Cell (2) · Disease Attributes (1) · Leukemia (1)
pembrolizumab (2) · Biopsy (1) · Cyclophosphamide (1) · Dimethyl Fumarate (1) · Doxorubicin (1) · Everolimus (1) · Lenalidomide (1) · Light (1) · Methoxsalen (1) · Prednisolone (1) · Radiotherapy (1) · TNTCFP protein (1) · Vincristine (1) · hypericin (1) · mogamulizumab (1)
Abramson Cancer Center at Penn Medicine (1) · Columbia University (1) · Ellen Kim, MD (1) · Florida Academic Dermatology Centers (1) · Galderma R&D (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Samsung Medical Center (1) · University College, London (1) · University of Michigan Rogel Cancer Center (1) · Universitätsmedizin Mannheim (1)
United States (8) · Germany (2) · Australia (1) · China (1) · France (1) · South Korea (1) · United Kingdom (1)
Alain H Rook, M.D. (1) · James Gulley, M.D. (1) · Jonathan Brammer, MD (1) · Larisa Geskin, MD (1) · Ryan Wilcox (1) · Tim Illidge (1) · Won Seog Kim, MD, PhD (1)
PMID 19826128, PMID 21355097, PMID 25891346, PMID 26228486, PMID 28264616, PMID 32632956, PMID 33072126, PMID 37217183, PMID 39821757
2017 (1)